Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MoonLake Immunotherapeutics (MLTX)
USD19.35
-0.17 (-0.87%)
CH NASDAQ Healthcare Biotechnology
Address
Dorfstrasse 29 6300
Zug, CH
Zug, CH
CEO
Jorge Santos da Silva
Website
moonlaketx.com
IPO
2020-10-20
CIK 1821586 ISIN KY61559X1045
Description
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD19.35
-0.17 (-0.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.04
Float Shares
64.25M
Free Float %
88.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.43% | +7.60% | +4.90% | +20.69% | +47.53% | +42.94% | -53.11% | -32.03% | +88.40% | +79.60% | +79.60% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
19.35
Low
10.00
-48.3%
Consensus
28.50
+47.3%
Median
29.50
+52.5%
High
45.00
+132.6%
DCF (Unlevered)
4.08
-78.9%
DCF (Levered)
4.01
-79.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 11 | 0 |
| Hold | 2 | 0 |
| Sell | 2 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
45.00
+132.6%
|
| Last Quarter | 2 |
40.00
+106.7%
|
| Last Year | 15 |
24.47
+26.5%
|
| All Time | 19 |
35.37
+82.8%
|
Quality scores
Altman Z-Score
2.78
Grey zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-86.8% Q1'26: -55.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.5% ★ Q1'26: +12.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.34×
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 EPS Ana. |
Dec 2027 10 Rev. Ana. 9 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
Dec 2029 4 Rev. Ana. 6 EPS Ana. |
Dec 2030 4 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
22.33M
16.07M – 31.20M
|
132.33M
95.23M – 184.89M
+492.7% YoY
|
434.46M
312.65M – 607.02M
+228.3% YoY
|
817.46M
588.27M – 1.14B
+88.2% YoY
|
| EBITDA |
-141.71M
|
-219.85M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-143.09M
|
-222.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-118.94M
est: -110.82M (-7.3%)
|
-227.32M
est: -227.32M (+0.0%)
|
-271.20M
-290.93M – -186.47M
-19.3% YoY
|
-231.42M
-289.94M – -172.90M
+14.7% YoY
|
-237.27M
-358.68M – -64.47M
-2.5% YoY
|
-68.83M
-104.37M – -43.74M
+71.0% YoY
|
129.21M
82.11M – 195.92M
+287.7% YoY
|
| SGA |
30.32M
|
41.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.89
est: -1.79 (-5.7%)
|
-3.53
est: -3.57 (+1.0%)
|
-3.72
-4.51 – -2.89
-4.3% YoY
|
-3.73
-4.50 – -2.68
-0.4% YoY
|
-3.02
-5.56 – -1.00
+19.1% YoY
|
-1.07
-1.62 – -0.68
+64.7% YoY
|
2.00
1.27 – 3.04
+287.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-11 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
25
Total invested
33.93M
Insider transactions (90d)
0
Beneficial owners (>5%)
31
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVF INC. | 21.75M | 58.90% | — | — | — | 21.75M | CO | — | 2022-04-18 | ↗ |
| 2 | BVF PARTNERS L.P. | 21.75M | 58.90% | — | — | — | 21.75M | IA, PN | — | 2022-04-18 | ↗ |
| 3 | MARK N. LAMPERT | 21.75M | 58.90% | — | — | — | 21.75M | IN | — | 2022-04-18 | ↗ |
| 4 | BVF GP HOLDINGS LLC | 20.27M | 54.90% | — | — | — | 20.27M | OO | — | 2022-04-18 | ↗ |
| 5 | BIOTECHNOLOGY VALUE FUND, L.P. | 11.27M | 30.50% | — | — | — | 11.27M | PN | — | 2022-04-18 | ↗ |
| 6 | BVF I GP LLC | 11.27M | 30.50% | — | — | — | 11.27M | OO | — | 2022-04-18 | ↗ |
| 7 | BIOTECHNOLOGY VALUE FUND II, L.P. | 9.01M | 24.40% | — | — | — | 9.01M | PN | — | 2022-04-18 | ↗ |
| 8 | BVF II GP LLC | 9.01M | 24.40% | — | — | — | 9.01M | OO | — | 2022-04-18 | ↗ |
| 9 | Bihua Chen | 6.89M | 17.60% | — | 6.89M | — | — | HC, IN | United States | 2023-03-31 | ↗ |
| 10 | Abigail P. Johnson | 3.85M | 6.42% | — | — | 3.85M | — | IN | United States of America | 2024-02-09 | ↗ |
| 11 | FMR LLC | 3.85M | 6.42% | 3.85M | — | 3.85M | — | HC | Delaware | 2024-02-09 | ↗ |
| 12 | E.Merck KG, Darmstadt Germany | 3.33M | 8.30% | 3.33M | — | 3.33M | — | CO | Germany | 2022-08-03 | ↗ |
| 13 | Merck Healthcare KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany | 3.33M | 8.30% | 3.33M | — | 3.33M | — | CO | Germany | 2022-08-03 | ↗ |
| 14 | Merck KGaA, Darmstadt, Germany | 3.33M | 8.30% | 3.33M | — | 3.33M | — | CO | Germany | 2022-08-03 | ↗ |
| 15 | BIOTECHNOLOGY VALUE TRADING FUND OS, L.P. | 1.42M | 3.90% | — | — | — | 1.42M | PN | — | 2022-04-18 | ↗ |
| 16 | BVF PARTNERS OS LTD. | 1.42M | 3.90% | — | — | — | 1.42M | CO | — | 2022-04-18 | ↗ |
| 17 | Adage Capital Advisors, L.L.C. | 1.01M | 8.44% | — | 1.01M | — | — | OO | Delaware | 2020-11-02 | ↗ |
| 18 | Adage Capital Partners GP, L.L.C. | 1.01M | 8.44% | — | 1.01M | — | — | OO | Delaware | 2020-11-02 | ↗ |
| 19 | Adage Capital Partners, L.P. | 1.01M | 8.44% | — | 1.01M | — | — | PN | Delaware | 2020-11-02 | ↗ |
| 20 | Phillip Gross | 1.01M | 8.44% | — | 1.01M | — | — | IN | United States | 2020-11-02 | ↗ |
| 21 | Robert Atchinson | 1.01M | 8.44% | — | 1.01M | — | — | IN | United States | 2020-11-02 | ↗ |
| 22 | RTW Investments, LP | 750.0K | 6.29% | — | 750.0K | — | 750.0K | IA, PN, OO | OR PLACE OF ORGANIZATION | 2021-02-16 | ↗ |
| 23 | Roderick Wong | 750.0K | 6.29% | — | 750.0K | — | 750.0K | HC, IN | OR PLACE OF ORGANIZATION | 2021-02-16 | ↗ |
| 24 | 52-0556948 | 746.9K | 6.20% | 88.4K | — | 746.9K | — | IA | Maryland | 2022-02-14 | ↗ |
| 25 | Peter Kolchinsky | 700.0K | 5.90% | — | 700.0K | — | 700.0K | HC, IN | Delaware | 2021-02-16 | ↗ |
| 26 | RA Capital Management, L.P. | 700.0K | 5.90% | — | 700.0K | — | 700.0K | IA, PN | Delaware | 2021-02-16 | ↗ |
| 27 | Rajeev Shah | 700.0K | 5.90% | — | 700.0K | — | 700.0K | HC, IN | Delaware | 2021-02-16 | ↗ |
| 28 | RA Capital Healthcare Fund, L.P. | 635.3K | 5.30% | — | 635.3K | — | 635.3K | PN | Delaware | 2021-02-16 | ↗ |
| 29 | Citadel Advisors LLC | 10.00 | 5.70% | — | 685.9K | — | — | IA, HC, OO | Delaware | 2021-02-16 | ↗ |
| 30 | CALC IV LP | 6.00 | 0.10% | — | 685.9K | — | — | HC, PN | Delaware | 2020-11-02 | ↗ |
| 31 | SPIKE LOY | — | 0.00% | — | — | — | — | IN | — | 2022-04-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
25
-120 vs prev Q
New positions
4
Closed positions
110
Increased
11
Reduced
7
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 175.7K +175.7K (+100.0%) | 2.32B +2.3B (+100.0%) | 0.28% +0.277 pp | 2.29% +2.291 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 2 | BVF INC/IL | 19.75M +— (+0.0%) | 260.32M +118.7M (+83.8%) | 31.17% -0.043 pp | 8.76% +3.022 pp | USD5.25 +151.0% | 15 qtrs — |
| 3 | DEEP TRACK CAPITAL, LP | 4.61M +4.6M (+100.0%) | 60.76M +60.8M (+100.0%) | 7.27% +7.275 pp | 1.08% +1.083 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 4 | CORMORANT ASSET MANAGEMENT, LP | 4.36M +2.4M (+118.4%) | 57.40M +43.1M (+301.5%) | 6.87% +3.722 pp | 2.65% +1.668 pp | USD14.40 -8.5% | 15 qtrs — |
| 5 | D. E. SHAW & CO., INC. | 2.48M +2.5M (+100.0%) | 32.70M +32.7M (+100.0%) | 3.91% +3.915 pp | 0.02% +0.018 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 6 | JANUS HENDERSON GROUP PLC | 2.10M +2.1M (+18,782.8%) | 27.66M +27.6M (+34,698.6%) | 3.31% +3.290 pp | 0.01% +0.012 pp | USD13.41 -1.7% | 10 qtrs — |
| 7 | LOGOS GLOBAL MANAGEMENT LP | 1.75M +1.8M (+100.0%) | 23.07M +23.1M (+100.0%) | 2.76% +2.762 pp | 1.39% +1.394 pp | USD13.18 +0.0% | 4 qtrs — |
| 8 | JANE STREET GROUP, LLC | 1.68M +1.7M (+7,553.8%) | 22.17M +22.0M (+13,969.3%) | 2.65% +2.620 pp | 0.00% +0.003 pp | USD13.10 +0.6% | 12 qtrs — |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 1.57M -128.2K (-7.5%) | 20.71M +8.5M (+70.0%) | 2.48% -0.206 pp | 0.03% +0.011 pp | USD17.28 -23.7% | 14 qtrs — |
| 10 | MORGAN STANLEY | 1.04M +787.9K (+307.0%) | 13.77M +11.9M (+648.1%) | 1.65% +1.243 pp | 0.00% +0.001 pp | USD13.45 -2.0% | 14 qtrs — |
| 11 | VIVO CAPITAL, LLC | 1.00M +1.0M (+100.0%) | 13.18M +13.2M (+100.0%) | 1.58% +1.578 pp | 0.85% +0.852 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 959.6K +136.6K (+16.6%) | 12.65M +6.7M (+114.3%) | 1.51% +0.214 pp | 0.00% +0.001 pp | USD36.56 -63.9% | 15 qtrs — |
| 13 | JPMORGAN CHASE & CO | 837.7K +663.6K (+381.0%) | 11.04M +9.8M (+784.2%) | 1.32% +1.047 pp | 0.00% +0.001 pp | USD13.81 -4.6% | 13 qtrs — |
| 14 | MILLENNIUM MANAGEMENT LLC | 802.7K +713.6K (+800.2%) | 10.58M +9.9M (+1,554.8%) | 1.27% +1.126 pp | 0.00% +0.004 pp | USD12.51 +5.4% | 12 qtrs — |
| 15 | TWO SIGMA INVESTMENTS, LP | 784.8K +330.5K (+72.8%) | 10.34M +7.1M (+217.6%) | 1.24% +0.521 pp | 0.01% +0.010 pp | USD9.70 +35.9% | 4 qtrs — |
| 16 | POINT72 ASSET MANAGEMENT, L.P. | 772.5K +762.7K (+7,782.7%) | 10.18M +10.1M (+14,390.0%) | 1.22% +1.204 pp | 0.01% +0.011 pp | USD13.61 -3.2% | 5 qtrs — |
| 17 | NUVEEN, LLC | 637.4K +1.7K (+0.3%) | 8.40M +3.8M (+84.3%) | 1.01% +0.001 pp | 0.00% +0.001 pp | USD40.21 -67.2% | 4 qtrs — |
| 18 | HRT FINANCIAL LP | 635.9K +492.6K (+343.8%) | 8.38M +7.4M (+716.1%) | 1.00% +0.777 pp | 0.03% +0.023 pp | USD11.83 +11.4% | 2 qtrs — |
| 19 | JEFFERIES FINANCIAL GROUP INC. | 500.0K +475.0K (+1,900.0%) | 6.59M +6.4M (+3,576.4%) | 0.79% +0.750 pp | 0.03% +0.033 pp | USD13.31 -1.0% | 5 qtrs — |
| 20 | VOLEON CAPITAL MANAGEMENT LP | 499.1K +458.8K (+1,139.3%) | 6.58M +6.3M (+2,178.1%) | 0.79% +0.724 pp | 0.14% +0.134 pp | USD12.70 +3.8% | 2 qtrs — |
| 21 | JUMP FINANCIAL, LLC | 425.6K +425.6K (+100.0%) | 5.61M +5.6M (+100.0%) | 0.67% +0.672 pp | 0.07% +0.069 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 22 | SOLEUS CAPITAL MANAGEMENT, L.P. | 400.0K +400.0K (+100.0%) | 5.27M +5.3M (+100.0%) | 0.63% +0.631 pp | 0.19% +0.195 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 23 | CITADEL ADVISORS LLC | 380.9K +331.6K (+672.1%) | 5.02M +4.7M (+1,319.2%) | 0.60% +0.523 pp | 0.00% +0.001 pp | USD13.63 -3.3% | 15 qtrs — |
| 24 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 364.0K +157.0K (+75.8%) | 4.80M +3.3M (+223.2%) | 0.57% +0.247 pp | 0.45% +0.284 pp | USD13.71 -3.9% | 4 qtrs — |
| 25 | STEMPOINT CAPITAL LP | 348.4K +348.4K (+100.0%) | 4.59M +4.6M (+100.0%) | 0.55% +0.550 pp | 0.79% +0.787 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 26 | WEISS ASSET MANAGEMENT LP | 333.0K +333.0K (+100.0%) | 4.39M +4.4M (+100.0%) | 0.53% +0.525 pp | 0.06% +0.061 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 27 | J. GOLDMAN & CO LP | 328.4K +291.2K (+782.8%) | 4.33M +4.1M (+1,522.8%) | 0.52% +0.459 pp | 0.11% +0.107 pp | USD13.47 -2.2% | 4 qtrs — |
| 28 | SCHONFELD STRATEGIC ADVISORS LLC | 322.3K -643.1K (-66.6%) | 4.25M -2.7M (-38.6%) | 0.51% -1.017 pp | 0.02% -0.021 pp | USD7.17 +83.8% | 12 qtrs — |
| 29 | BLACKROCK, INC. | 286.6K +161.2K (+128.6%) | 3.78M +2.9M (+320.2%) | 0.45% +0.254 pp | 0.00% +0.000 pp | USD29.30 -55.0% | 6 qtrs — |
| 30 | BOXER CAPITAL MANAGEMENT, LLC | 275.0K +25.0K (+10.0%) | 3.62M +1.8M (+102.2%) | 0.43% +0.039 pp | 0.79% +0.222 pp | USD7.72 +70.7% | 2 qtrs — |
| 31 | GOLDMAN SACHS GROUP INC | 270.7K -92.2K (-25.4%) | 3.57M +965.6K (+37.1%) | 0.43% -0.146 pp | 0.00% +0.000 pp | USD45.57 -71.1% | 15 qtrs — |
| 32 | VANGUARD GROUP INC | 266.2K +145.9K (+121.3%) | 3.51M +2.6M (+306.9%) | 0.42% +0.230 pp | 0.00% +0.000 pp | USD32.28 -59.2% | 10 qtrs — |
| 33 | FIRST TURN MANAGEMENT, LLC | 262.6K +— (+0.0%) | 3.46M +1.6M (+83.8%) | 0.41% -0.001 pp | 0.40% +0.113 pp | USD7.17 +83.8% | 4 qtrs — |
| 34 | 683 CAPITAL MANAGEMENT, LLC | 255.4K +255.4K (+100.0%) | 3.37M +3.4M (+100.0%) | 0.40% +0.403 pp | 0.15% +0.146 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 35 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 254.0K +254.0K (+100.0%) | 3.35M +3.3M (+100.0%) | 0.40% +0.401 pp | 0.05% +0.052 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 36 | UBS GROUP AG | 239.0K +154.7K (+183.4%) | 3.15M +2.5M (+420.9%) | 0.38% +0.244 pp | 0.00% +0.000 pp | USD22.88 -42.4% | 15 qtrs — |
| 37 | ALGERT GLOBAL LLC | 221.6K +221.6K (+100.0%) | 2.92M +2.9M (+100.0%) | 0.35% +0.350 pp | 0.05% +0.046 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 38 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 213.0K +213.0K (+100.0%) | 2.81M +2.8M (+100.0%) | 0.34% +0.336 pp | 0.02% +0.022 pp | USD13.18 +0.0% | 3 qtrs — |
| 39 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 198.3K +198.3K (+100.0%) | 2.61M +2.6M (+100.0%) | 0.31% +0.313 pp | 0.11% +0.112 pp | USD13.18 +0.0% | 12 qtrs — |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 195.7K +87.6K (+81.0%) | 2.58M +1.8M (+232.8%) | 0.31% +0.138 pp | 0.00% +0.000 pp | USD26.96 -51.1% | 10 qtrs — |
| 41 | EAGLE HEALTH INVESTMENTS LP | 187.6K +187.6K (+100.0%) | 2.47M +2.5M (+100.0%) | 0.30% +0.296 pp | 0.54% +0.543 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 42 | TREXQUANT INVESTMENT LP | 184.3K +184.3K (+100.0%) | 2.43M +2.4M (+100.0%) | 0.29% +0.291 pp | 0.02% +0.022 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 43 | DIMENSIONAL FUND ADVISORS LP | 183.6K +172.6K (+1,568.4%) | 2.42M +2.3M (+2,966.8%) | 0.29% +0.272 pp | 0.00% +0.001 pp | USD15.64 -15.7% | 5 qtrs — |
| 44 | FMR LLC | 156.3K -570.7K (-78.5%) | 2.06M -3.2M (-60.5%) | 0.25% -0.902 pp | 0.00% 0.000 pp | USD49.73 -73.5% | 15 qtrs — |
| 45 | RENAISSANCE TECHNOLOGIES LLC | 134.5K +134.5K (+100.0%) | 1.77M +1.8M (+100.0%) | 0.21% +0.212 pp | 0.00% +0.003 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 46 | CANDRIAM S.C.A. | 134.3K +687.0 (+0.5%) | 1.77M +812.3K (+84.8%) | 0.21% +0.001 pp | 0.01% +0.004 pp | USD57.50 -77.1% | 9 qtrs — |
| 47 | TWO SIGMA ADVISERS, LP | 131.7K +92.4K (+234.9%) | 1.74M +1.5M (+515.6%) | 0.21% +0.146 pp | 0.00% +0.003 pp | USD11.39 +15.7% | 4 qtrs — |
| 48 | AMERIPRISE FINANCIAL INC | 131.0K +129.1K (+7,009.9%) | 1.73M +1.7M (+12,961.9%) | 0.21% +0.204 pp | 0.00% +0.000 pp | USD13.72 -3.9% | 6 qtrs — |
| 49 | RICE HALL JAMES & ASSOCIATES, LLC | 127.5K -7.4K (-5.5%) | 1.68M +713.2K (+73.8%) | 0.20% -0.012 pp | 0.09% +0.040 pp | USD49.14 -73.2% | 6 qtrs — |
| 50 | TD ASSET MANAGEMENT INC | 126.7K +20.1K (+18.9%) | 1.67M +906.1K (+118.5%) | 0.20% +0.032 pp | 0.00% +0.001 pp | USD38.09 -65.4% | 15 qtrs — |
| 51 | SQUAREPOINT OPS LLC | 121.6K +91.0K (+296.4%) | 1.60M +1.4M (+628.6%) | 0.19% +0.144 pp | 0.00% +0.002 pp | USD16.31 -19.2% | 11 qtrs — |
| 52 | CENTIVA CAPITAL, LP | 105.7K -27.2K (-20.5%) | 1.39M +440.2K (+46.2%) | 0.17% -0.043 pp | 0.01% +0.002 pp | USD7.17 +83.8% | 2 qtrs — |
| 53 | TUDOR INVESTMENT CORP ET AL | 103.5K +103.5K (+100.0%) | 1.36M +1.4M (+100.0%) | 0.16% +0.163 pp | 0.00% +0.003 pp | USD13.18 +0.0% | 11 qtrs — |
| 54 | Y-INTERCEPT (HONG KONG) LTD | 96.0K +96.0K (+100.0%) | 1.26M +1.3M (+100.0%) | 0.15% +0.151 pp | 0.03% +0.028 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 55 | GSA CAPITAL PARTNERS LLP | 89.2K +89.2K (+100.0%) | 1.18M +1.2M (+100.0%) | 0.14% +0.141 pp | 0.10% +0.101 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 56 | WALLEYE TRADING LLC | 87.4K +33.7K (+62.7%) | 1.15M +766.8K (+199.1%) | 0.14% +0.053 pp | 0.00% +0.001 pp | USD9.49 +38.9% | 2 qtrs — |
| 57 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 85.6K +20.3K (+31.1%) | 1.13M +662.1K (+141.5%) | 0.14% +0.032 pp | 0.00% +0.001 pp | USD34.15 -61.4% | 12 qtrs — |
| 58 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 78.6K +78.6K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.12% +0.124 pp | 0.01% +0.011 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 59 | GEODE CAPITAL MANAGEMENT, LLC | 72.6K +10.2K (+16.4%) | 956.4K +509.4K (+114.0%) | 0.11% +0.016 pp | 0.00% +0.000 pp | USD36.15 -63.5% | 13 qtrs — |
| 60 | FOX RUN MANAGEMENT, L.L.C. | 72.0K +60.6K (+531.2%) | 948.5K +866.7K (+1,060.4%) | 0.11% +0.096 pp | 0.15% +0.134 pp | USD12.23 +7.8% | 2 qtrs — |
| 61 | CONGRESS ASSET MANAGEMENT CO /MA | 71.1K -2.3K (-3.1%) | 937.0K +411.0K (+78.1%) | 0.11% -0.004 pp | 0.01% +0.003 pp | USD50.43 -73.9% | 6 qtrs — |
| 62 | JAIN GLOBAL LLC | 70.6K +70.6K (+100.0%) | 930.7K +930.7K (+100.0%) | 0.11% +0.111 pp | 0.00% +0.005 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 63 | LION POINT CAPITAL, LP | 67.5K +— (+0.0%) | 889.7K +405.7K (+83.8%) | 0.11% 0.000 pp | 4.60% +1.854 pp | USD7.17 +83.8% | 2 qtrs — |
| 64 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 61.9K +61.7K (+22,675.0%) | 817.0K +815.0K (+40,750.0%) | 0.10% +0.097 pp | 0.00% +0.001 pp | USD13.32 -1.1% | 3 qtrs — |
| 65 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 61.7K +33.5K (+118.8%) | 813.2K +611.0K (+302.2%) | 0.10% +0.053 pp | 0.04% +0.030 pp | USD10.43 +26.4% | 2 qtrs — |
| 66 | SWISS NATIONAL BANK | 61.5K +18.5K (+43.0%) | 810.6K +502.3K (+162.9%) | 0.10% +0.029 pp | 0.00% +0.000 pp | USD41.98 -68.6% | 10 qtrs — |
| 67 | ACUTA CAPITAL PARTNERS, LLC | 59.3K +59.3K (+100.0%) | 781.3K +781.3K (+100.0%) | 0.09% +0.094 pp | 0.53% +0.531 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 68 | ALPS ADVISORS INC | 58.2K +27.4K (+89.1%) | 766.7K +546.1K (+247.7%) | 0.09% +0.043 pp | 0.00% +0.003 pp | USD36.14 -63.5% | 9 qtrs — |
| 69 | WALLEYE CAPITAL LLC | 54.6K +43.0K (+370.7%) | 719.6K +636.5K (+765.2%) | 0.09% +0.068 pp | 0.00% +0.002 pp | USD11.90 +10.8% | 2 qtrs — |
| 70 | STATE STREET CORP | 51.0K -1.9K (-3.6%) | 671.8K +292.6K (+77.2%) | 0.08% -0.003 pp | 0.00% +0.000 pp | USD52.51 -74.9% | 10 qtrs — |
| 71 | BARCLAYS PLC | 50.3K +44.6K (+790.8%) | 662.3K +377.9K (+132.9%) | 0.08% +0.070 pp | 0.00% +0.000 pp | USD15.65 -15.8% | 10 qtrs — |
| 72 | QUADRATURE CAPITAL LTD | 50.2K +50.2K (+100.0%) | 661.9K +661.9K (+100.0%) | 0.08% +0.079 pp | 0.01% +0.007 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 73 | WOODLINE PARTNERS LP | 49.2K -11.7K (-19.2%) | 648.0K +211.7K (+48.5%) | 0.08% -0.019 pp | 0.00% +0.001 pp | USD51.71 -74.5% | 11 qtrs — |
| 74 | DIADEMA PARTNERS LP | 47.2K +21.1K (+80.8%) | 622.1K +435.0K (+232.4%) | 0.07% +0.033 pp | 0.11% +0.059 pp | USD9.86 +33.7% | 2 qtrs — |
| 75 | CINCTIVE CAPITAL MANAGEMENT LP | 37.2K +37.2K (+100.0%) | 490.2K +490.2K (+100.0%) | 0.06% +0.059 pp | 0.03% +0.027 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 76 | IMC-CHICAGO, LLC | 36.5K +36.5K (+100.0%) | 480.6K +480.6K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 77 | AQR CAPITAL MANAGEMENT LLC | 32.9K +32.9K (+100.0%) | 433.4K +433.4K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 78 | GROUP ONE TRADING, L.P. | 30.5K +15.0K (+97.0%) | 401.7K +290.8K (+262.2%) | 0.05% +0.024 pp | 0.00% +0.001 pp | USD10.13 +30.1% | 2 qtrs — |
| 79 | ENTROPY TECHNOLOGIES, LP | 30.3K +30.3K (+100.0%) | 399.4K +399.4K (+100.0%) | 0.05% +0.048 pp | 0.02% +0.022 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 80 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 29.3K +10.3K (+54.4%) | 386.1K +250.1K (+183.9%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD40.35 -67.3% | 10 qtrs — |
| 81 | SIMPLEX TRADING, LLC | 29.0K -29.3K (-50.2%) | 381.9K -35.2K (-8.4%) | 0.05% -0.046 pp | 0.00% +0.000 pp | USD7.17 +83.8% | 2 qtrs — |
| 82 | AXIOM INVESTORS LLC /DE | 26.0K +818.0 (+3.2%) | 342.7K +162.1K (+89.8%) | 0.04% +0.001 pp | 0.00% +0.002 pp | USD7.36 +79.1% | 2 qtrs — |
| 83 | GRAHAM CAPITAL MANAGEMENT, L.P. | 24.3K +24.3K (+100.0%) | 320.2K +320.2K (+100.0%) | 0.04% +0.038 pp | 0.01% +0.008 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 84 | XTX TOPCO LTD | 23.0K -9.3K (-28.8%) | 302.8K +71.6K (+31.0%) | 0.04% -0.015 pp | 0.01% -0.004 pp | USD7.17 +83.8% | 4 qtrs — |
| 85 | SG AMERICAS SECURITIES, LLC | 21.9K +4.4K (+24.9%) | 288.0K +162.0K (+128.6%) | 0.03% +0.007 pp | 0.00% 0.000 pp | USD8.37 +57.5% | 2 qtrs — |
| 86 | MARINER, LLC | 20.2K +20.2K (+100.0%) | 265.7K +265.7K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD13.18 +0.0% | 1 qtrs NEW |
| 87 | NORTHERN TRUST CORP | 18.5K -26.5K (-58.9%) | 243.6K -79.2K (-24.5%) | 0.03% -0.042 pp | 0.00% +0.000 pp | USD22.42 -41.2% | 10 qtrs — |
| 88 | VIRTUS INVESTMENT ADVISERS, INC. | 18.0K +15.4K (+595.8%) | 237.1K +218.5K (+1,179.1%) | 0.03% +0.024 pp | 0.06% +0.059 pp | USD16.10 -18.1% | 4 qtrs — |
| 89 | LEGAL & GENERAL GROUP PLC | 16.1K -4.8K (-23.1%) | 211.9K +62.0K (+41.4%) | 0.03% -0.008 pp | 0.00% +0.000 pp | USD43.94 -70.0% | 7 qtrs — |
| 90 | SKOPOS LABS, INC. | 14.9K +14.9K (+100.0%) | 204.3K +204.3K (+100.0%) | 0.02% +0.024 pp | 0.01% +0.009 pp | USD13.18 +0.0% | 5 qtrs — |
| 91 | VIDENT ADVISORY, LLC | 15.4K +15.4K (+100.0%) | 203.6K +203.6K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.002 pp | USD13.18 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.67% | 386.0K | 0.65% |
| 2 | T. Rowe Price Innovation Leaders ETF TNXT | 0.09% | 17.1K | 0.49% |
| 3 | iShares ESG Aware MSCI USA Small-Cap ETF ESML | 0.06% | 1.67M | 0.17% |
| 4 | T. Rowe Price Capital Appreciation Equity ETF TCAF | 0.05% | 4.20M | 0.31% |
| 5 | Nuveen ESG Small-Cap ETF NUSC | 0.05% | 690.2K | 0.31% |
| 6 | iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETF CUSS.L | 0.02% | 543.0K | 0.43% |
| 7 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.01% | 66.0K | 0.10% |
| 8 | Vanguard Health Care ETF VHT | 0.01% | 2.06M | 0.09% |
| 9 | Fidelity MSCI Health Care Index ETF FHLC | 0.01% | 330.5K | 0.08% |
| 10 | Vanguard MSCI International Small Cos Index ETF VISM.AX | 0.01% | 43.2K | 0.32% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
5
Shares acquired
—
Shares disposed
240.2K
Cash buys
—
Cash sales
5.00
Net activity
-240,221
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | Bodenstedt Matthias | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 2,426 | 19.56 | 47.5K | 1,186,084 | D | ↗ |
| 2026-04-13 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 51,873 | 18.23 | 945.6K | 2,924,893 | D | ↗ |
| 2026-04-10 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 98,127 | 18.41 | 1.81M | 2,976,766 | D | ↗ |
| 2026-04-10 | Bodenstedt Matthias | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 1,925 | 19.51 | 37.6K | 1,188,510 | D | ↗ |
| 2026-04-09 | Bodenstedt Matthias | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 85,870 | 18.94 | 1.63M | 1,190,435 | D | ↗ |
| 2026-03-31 | BVF PARTNERS L P/IL | Director / 10% Owner | S-Sale | D | Class A Ordinary Shares, $0.0001 par value | 1,932,354 | 16.79 | 32.44M | 8,302,735 | D | ↗ |
| 2026-01-07 | Santos da Silva Jorge | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 520,342 | 11.29 | 5.87M | 520,342 | D | ↗ |
| 2026-01-07 | Reich Kristian | Officer | A-Award | A | Stock Option (Right to Buy) | 520,342 | 11.29 | 5.87M | 520,342 | D | ↗ |
| 2026-01-07 | Bodenstedt Matthias | Officer | A-Award | A | Class A ordinary shares, par value $0.0001 per share | 354,296 | 0.00 | — | 1,276,305 | D | ↗ |
| 2025-12-19 | Santos da Silva Jorge | Director / Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 196,316 | 0.00 | — | 3,074,893 | D | ↗ |
| 2025-12-19 | Reich Kristian | Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 35,389 | 0.00 | — | 35,389 | D | ↗ |
| 2025-12-19 | Bodenstedt Matthias | Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 294,473 | 0.00 | — | 922,009 | D | ↗ |
| 2025-12-09 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 70,000 | 14.49 | 1.01M | 2,878,577 | D | ↗ |
| 2025-12-09 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 72,908 | 14.43 | 1.05M | 0 | D | ↗ |
| 2025-12-08 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 130,000 | 15.08 | 1.96M | 2,948,577 | D | ↗ |
| 2025-12-08 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 130,000 | 15.08 | 1.96M | 72,908 | D | ↗ |
| 2025-10-08 | Bodenstedt Matthias | Officer | P-Purchase | A | Class A ordinary shares, par value $0.0001 per share | 10,870 | 9.09 | 98.8K | 627,536 | D | ↗ |
| 2025-09-30 | Chen Bihua | 10% Owner | S-Sale | D | Class A Ordinary Shares | 5,827 | 6.96 | 40.6K | 1,994,173 | I | ↗ |
| 2025-09-29 | Chen Bihua | 10% Owner | S-Sale | D | Class A Ordinary Shares | 70,748 | 9.38 | 663.6K | 8,423,403 | I | ↗ |
| 2025-09-02 | Reich Kristian | Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 48,978 | 0.00 | — | 202,908 | D | ↗ |
| 2025-07-03 | Moukheibir Catherine | Director | M-Exempt | A | Class A ordinary shares, par value $0.0001 per share | 23,500 | 0.00 | — | 23,500 | D | ↗ |
| 2025-06-05 | Xavier Ramnik | Director | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | D | ↗ |
| 2025-06-05 | Sturge Simon | Director | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | D | ↗ |
| 2025-06-05 | Phillips Andrew John | Director | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | D | ↗ |
| 2025-06-05 | Moukheibir Catherine | Director | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | D | ↗ |
| 2025-06-05 | Loy Spike | Director | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | D | ↗ |
| 2025-06-05 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Option to Buy | 6,682 | 48.83 | 326.3K | 6,682 | I | ↗ |
| 2025-02-27 | Santos da Silva Jorge | Director / Officer | A-Award | A | Class A ordinary shares, par value $0.0001 per share | 95,763 | 0.00 | — | 3,078,577 | D | ↗ |
| 2025-02-27 | Reich Kristian | Officer | A-Award | A | Stock Option (Right to Buy) | 139,273 | 41.77 | 5.82M | 139,273 | D | ↗ |
| 2025-02-27 | Bodenstedt Matthias | Officer | A-Award | A | Class A ordinary shares, par value $0.0001 per share | 95,763 | 0.00 | — | 616,666 | D | ↗ |
| 2025-01-20 | Reich Kristian | Officer | C-Conversion | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 3,328 | 0.00 | — | 2,508 | D | ↗ |
| 2024-10-04 | Sturge Simon | Director | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 171,000 | 53.72 | 9.19M | 171,980 | D | ↗ |
| 2024-10-04 | BVF PARTNERS L P/IL | Director / 10% Owner | S-Sale | D | Class A Ordinary Shares, $0.0001 par value | 1,030,589 | 50.00 | 51.53M | 10,235,089 | D | ↗ |
| 2024-06-06 | Xavier Ramnik | Director | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-06-06 | Sturge Simon | Director | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-06-06 | Phillips Andrew John | Director | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-06-06 | Moukheibir Catherine | Director | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-06-06 | Loy Spike | Director | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-06-06 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Option to Buy | 7,688 | 42.44 | 326.3K | 7,688 | — | ↗ |
| 2024-02-29 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 4,740 | 55.89 | 264.9K | 2,982,814 | — | ↗ |
| 2024-02-28 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 56,065 | 55.00 | 3.08M | 2,987,554 | — | ↗ |
| 2024-02-28 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 31,910 | 55.00 | 1.76M | 2,925,573 | — | ↗ |
| 2024-02-27 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 62,810 | 55.00 | 3.45M | 3,043,619 | — | ↗ |
| 2024-02-27 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 29,491 | 55.00 | 1.62M | 2,957,483 | — | ↗ |
| 2024-02-21 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 1,125 | 55.27 | 62.2K | 3,106,429 | — | ↗ |
| 2024-02-21 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 569 | 55.30 | 31.5K | 99,502 | — | ↗ |
| 2024-02-20 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 20,000 | 57.44 | 1.15M | 3,107,554 | — | ↗ |
| 2024-02-20 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 10,000 | 57.43 | 574.3K | 100,071 | — | ↗ |
| 2024-02-16 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 20,000 | 60.15 | 1.20M | 3,127,554 | — | ↗ |
| 2024-02-16 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 10,000 | 60.15 | 601.5K | 110,071 | — | ↗ |
| 2024-02-15 | Santos da Silva Jorge | Director / Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 20,000 | 60.18 | 1.20M | 3,147,554 | — | ↗ |
| 2024-02-15 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 10,000 | 60.16 | 601.6K | 120,071 | — | ↗ |
| 2024-02-14 | Reich Kristian | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 10,000 | 62.43 | 624.3K | 130,071 | — | ↗ |
| 2023-12-20 | Bodenstedt Matthias | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 5,264 | 58.34 | 307.1K | 520,903 | — | ↗ |
| 2023-12-19 | Bodenstedt Matthias | Officer | S-Sale | D | Class A ordinary shares, par value $0.0001 per share | 94,736 | 59.22 | 5.61M | 526,167 | — | ↗ |
| 2023-10-05 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 58,839 | 59.90 | 3.52M | 8,494,151 | — | ↗ |
| 2023-10-04 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 67,814 | 57.32 | 3.89M | 8,435,312 | — | ↗ |
| 2023-10-03 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 150,487 | 57.25 | 8.62M | 8,367,498 | — | ↗ |
| 2023-10-02 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 74,911 | 57.37 | 4.30M | 8,217,011 | — | ↗ |
| 2023-10-01 | Sturge Simon | Director | C-Conversion | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 10,196 | 0.00 | — | 0 | — | ↗ |
| 2023-10-01 | Santos da Silva Jorge | Director / Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 140,071 | 0.00 | — | 3,167,554 | — | ↗ |
| 2023-10-01 | Reich Kristian | Officer | C-Conversion | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 75,136 | 0.00 | — | 0 | — | ↗ |
| 2023-10-01 | Bodenstedt Matthias | Officer | D-Return | D | Class C ordinary shares, par value $0.0001 per share | 62,972 | 0.00 | — | 294,473 | — | ↗ |
| 2023-06-30 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 800,000 | 50.00 | 40.00M | 4,927,100 | — | ↗ |
| 2023-06-26 | Chen Bihua | 10% Owner | P-Purchase | A | Class A Ordinary Shares | 59,787 | 49.82 | 2.98M | 4,049,397 | — | ↗ |
| 2023-06-08 | Xavier Ramnik | Director | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-06-08 | Sturge Simon | Director | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-06-08 | Phillips Andrew John | Director | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-06-08 | Moukheibir Catherine | Director | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-06-08 | Loy Spike | Director | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-06-08 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Option to Buy | 11,297 | 29.18 | 329.6K | 11,297 | — | ↗ |
| 2023-04-05 | Reich Kristian | Officer | C-Conversion | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 2,916 | 0.00 | — | 7,084 | — | ↗ |
| 2023-04-05 | Bodenstedt Matthias | Officer | C-Conversion | A | Class A ordinary shares, par value $0.0001 per share | 410,796 | 0.00 | — | 410,796 | — | ↗ |
| 2022-04-06 | Xavier Ramnik | Director | A-Award | A | Option to Buy | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-04-06 | Sturge Simon | Director | A-Award | A | Option to Buy | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-04-06 | Phillips Andrew John | Director | A-Award | A | Option to Buy | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-04-06 | Moukheibir Catherine | Director | A-Award | A | Option to Buy | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-04-05 | Xavier Ramnik | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Sturge Simon | Director | — | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 10,196 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Santos da Silva Jorge | Director / Officer | — | D | Class C ordinary shares, par value $0.0001 per share | 0 | 0.00 | — | 336,387 | — | ↗ |
| 2022-04-05 | Reich Kristian | Officer | — | D | Common shares, par value CHF 0.10 per share, of MoonLake AG | 10,000 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Phillips Andrew John | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Moukheibir Catherine | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Loy Spike | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Lassen Kara | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-05 | Helix Holdings LLC | 10% Owner | C-Conversion | A | Class A Ordinary Shares | 2,785,000 | 0.00 | — | 3,215,000 | — | ↗ |
| 2022-04-05 | Chen Bihua | Director | P-Purchase | A | Class A Ordinary Shares | 2,850,000 | 10.00 | 28.50M | 2,850,000 | — | ↗ |
| 2022-04-05 | Bodenstedt Matthias | Officer | — | D | Class C ordinary shares, par value $0.0001 per share | 0 | 0.00 | — | 410,796 | — | ↗ |
| 2022-04-05 | BVF PARTNERS L P/IL | Director / 10% Owner | — | D | Class A Ordinary Shares, $0.0001 par value | 0 | 0.00 | — | 1,420,317 | — | ↗ |
| 2020-10-22 | Helix Holdings LLC | Director / 10% Owner | P-Purchase | A | Class A Ordinary Shares | 430,000 | 10.00 | 4.30M | 430,000 | — | ↗ |
| 2020-10-22 | Chen Bihua | Director / Officer / 10% Owner | P-Purchase | A | Class A Ordinary Shares | 430,000 | 10.00 | 4.30M | 430,000 | — | ↗ |
| 2020-10-19 | Scollins Jay | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-19 | Schmid John P. | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-19 | Lewis Will | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-19 | Helix Holdings LLC | Director / 10% Owner | — | D | Class B Ordinary Shares | 2,785,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-19 | Chen Bihua | Director / Officer / 10% Owner | — | I | Class B Ordinary Shares | 2,785,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-19 | CHANG NANCY T | Director | — | D | Class B Ordinary Shares | 30,000 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
72.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Dr. Kristian Reich Chief Scientific Officer | 586.3K | 589.8K | — | — | — | 54.8K | 1.23M | 0.00% | ↗ |
| 2 | 2023 | Dr. Jorge Santos da Silva Chief Executive Officer | 586.3K | 589.8K | — | — | — | 22.1K | 1.20M | 0.00% | ↗ |
| 3 | 2023 | Matthias Bodenstedt Chief Financial Officer | 446.8K | 424.5K | — | — | — | 20.3K | 891.6K | 0.00% | ↗ |
| 4 | 2022 | Matthias Bodenstedt Chief Financial Officer | 324.9K | 243.7K | 5.04M | — | — | 19.7K | 5.63M | 89.56% | ↗ |
| 5 | 2022 | Dr. Kristian Reich Chief Scientific Officer | 460.3K | 632.9K | 3.36M | — | — | 109.8K | 4.57M | 73.65% | ↗ |
| 6 | 2022 | Dr. Jorge Santos da Silva Chief Executive Officer | 460.3K | 632.9K | 3.36M | — | — | 21.4K | 4.48M | 75.11% | ↗ |
| 7 | 2021 | Dr. Kristian Reich Chief Scientific Officer | 322.9K | — | 4.84M | — | — | 5.5K | 5.17M | 93.65% | ↗ |
| 8 | 2021 | Dr. Jorge Santos da Silva Chief Executive Officer | 230.1K | — | 4.84M | — | — | 11.0K | 5.08M | 95.25% | ↗ |
| 9 | 2021 | Matthias Bodenstedt Chief Financial Officer | 162.5K | — | 597.1K | — | — | 4.7K | 764.2K | 78.13% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kristian Reich | Co-Founder & Chief Scientific Officer | 795.5K | — |
| Jorge Santos da Silva | Co-Founder, Interim Chair of the Board & CEO | 787.3K | — |
| Matthias Bodenstedt | Chief Financial Officer | 626.5K | male |
| Nicolas Mosimann | General Counsel | — | male |
| Nuala Brennan | Chief Clinical Development Officer | — | female |
| Oliver Daltrop | Chief Technical Officer | — | male |
| Roman Akbar-Haase | Chief of Staff to the Executive Board | — | — |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | — | — |
| Carla Bretes | Director of Investor Relations & External Communications | — | female |
| Wulf Boecher | Chief Medical Officer | — | — |
| Joana Cortez | Associate Vice-President of Legal & Compliance | — | — |
| Luciana Marques | Associate Vice-President of HR, People and Culture | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MLTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
